ArticleJournal of biomedical optics2024
Simulating photodynamic therapy for the treatment of glioblastoma using Monte Carlo radiative transport.
Article in Journal of biomedical optics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A dual-wavelength blue laser platform for integrated diagnosis and therapy in glioblastoma: preclinical evidence.Lasers in medical science · 2026Article
- From Simulation to Therapy: Light Guidance Through Zirconium Dental Implants for Bone-Targeted Photodynamic Inactivation.Bioengineering (Basel, Switzerland) · 2026Article
- Brain-Targeted 5-ALA-CAT Liposomes (BACL) Alleviate Hypoxia and Enhance Photodynamic Therapy in a Murine Glioblastoma Flank Xenograft Model via Angiopep-2-Mediated Targeting.Pharmaceutics · 2026Article
- EF24 targets METTL3 to reprogram m6A methylation and induce ferroptosis: an epitranscriptomic mechanism with therapeutical potential for glioma.Cell communication and signaling : CCS · 2025Article
- Photodynamic therapy dosimetry: current status and the emerging challenge of immune stimulation.Journal of biomedical optics · 2025Review
- Prediction of the photodynamic therapy effect using digital breast phantoms from patients with breast cancer via Monte Carlo simulations.Journal of biomedical optics · 2025Article
- Prognostic Factors and Talaporfin Sodium Concentration in Photodynamic Therapy for Recurrent Grade 4 Glioma.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Devices and Methods for Dosimetry of Personalized Photodynamic Therapy of Tumors: A Review on Recent Trends.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Significance: Glioblastoma (GBM) is a rare but deadly form of brain tumor with a low median survival rate of 14.6 months, due to its resistance to treatment. An independent simulation of the INtraoperative photoDYnamic therapy for GliOblastoma (INDYGO) trial, a clinical trial aiming to treat the GBM resection cavity with photodynamic therapy (PDT) via a laser coupled balloon device, is demonstrated. Aim: To develop a framework providing increased understanding for the PDT treatment, its parameters, and their impact on the clinical outcome. Approach: We use Monte Carlo radiative transport techniques within a computational brain model containing a GBM to simulate light path and PDT effects. Treatment parameters (laser power, photosensitizer concentration, and irradiation time) are considered, as well as PDT's impact on brain tissue temperature. Results: The simulation suggests that 39% of post-resection GBM cells are killed at the end of treatment when using the standard INDYGO trial protocol (light fluence = Conclusions: With further development and optimization, the simulation could have potential clinical benefit and be used to help plan and optimize intraoperative PDT treatment for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.